Company intelligence / Profile preview

Micreos Human Health

Bilthoven, North Holland, Netherlands

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Micreos Human Health is a clinical-stage biotechnology company pioneering the development of targeted antibacterial solutions using endolysin technology. Unlike traditional antibiotics, the company's proprietary endolysins specifically target and kill pathogenic bacteria like Staphylococcus aureus while preserving the beneficial microbiome. Their lead clinical candidate, XZ.700, is being evaluated for inflammatory skin conditions such as atopic dermatitis. Micreos also markets over-the-counter products under the Gladskin brand, which utilize their Staphefekt enzyme to manage skin microbiome imbalances.

Therapeutic areas: EndocrinologyDermatologyInfectious Diseases
Modalities: Recombinant proteinEnzymeEndolysin
Industry: Biotech

Beyond the preview

Go deeper on Micreos Human Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Micreos Human Health.

Explore the full profile